Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1621 1625 3781
This examiner grants 66% of resolved cases
Kendall Nicole Heitmeier is an examiner in Art Unit 1621, part of Tech Center 3700. She has resolved 41 cases, which offers an emerging profile of her examination tendencies. Her allowance rate is 65.9 percent, indicating a generally positive environment for applicants. This 65.9 percent rate suggests that more than half of the applications she reviews result in a granted patent, provided the claims are well-supported. The 41 resolved cases provide an initial baseline for evaluating her prosecution style.
A standout feature of her profile is the interview lift of 41.0 percent. This is an exceptionally high lift, suggesting that interviews are one of the most effective tools available to practitioners. The 41.0 percent increase over the baseline allowance rate of 65.9 percent implies that verbal advocacy is highly persuasive or helpful in her decision-making process. Applicants should prioritize interviews as a central part of their strategy to maximize their chances of success in Art Unit 1621.
However, the median days to allowance is 1396. This is a longer timeline, indicating that prosecution in Tech Center 3700 can be a protracted process. Applicants should be prepared for a pendency of 1396 days. Despite the 1396-day median, the 65.9 percent allowance rate and the 41.0 percent interview lift provide a clear path forward for those willing to invest the necessary time and effort. The 1396-day duration is a critical factor for long-term planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18686168 | COMPOSITIONS AND METHODS FOR TREATMENT OF ALOPECIA AREATA | Non-Final OA | VERADERMICS INCORPORATED |
| 18725593 | BICYCLIC INHIBITORS OF NICOTINAMIDE NMETHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 18709983 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18725495 | POTENT AND SELECTIVE SMARCA2 DEGRADING CHIMERIC MOLECULES AS CANCER THERAPEUTICS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17768344 | COMPOSITIONS AND METHODS OF TREATMENT FOR INHIBITING CAPILLARY TUBE REGRESSION | Final Rejection | University of South Florida |
| 18686007 | OIL-IN-WATER EMULSION COSMETIC | Final Rejection | SHISEIDO COMPANY, LTD. |
| 18158670 | NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS | Non-Final OA | University of Houston System |
| 18736628 | BICYCLIC AMINES AS CDK2 INHIBITORS | Non-Final OA | Incyte Corporation |
| 18034890 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | Non-Final OA | Janssen Pharmaceutica NV |
| 18849277 | BLU-945 IN COMBINATION WITH OSIMERTINIB FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER | Non-Final OA | Blueprint Medicines Corporation |
| 18002928 | NOVEL HETEROARYL-SUBSTITUTED PYRAZINE DERIVATIVES AS PESTICIDES | Final Rejection | Elanco Animal Health GmbH |
| 17932200 | SELECTIVE P2X3 MODULATORS | Final Rejection | GlaxoSmithKline Intellectual Property (No.3) Limited |
| 18249209 | DOSING REGIMENS FOR CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | Final Rejection | MEDIC Life Sciences Inc. |
| 17775265 | BIFUNCTIONAL COMPOUNDS FOR GRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Non-Final OA | NURIX THERAPEUTICS, INC. |
| 17770264 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | Non-Final OA | The University of Vermont and State Agriculture College |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy